The potential impact of neoadjuvant therapy and the role of circulating tumor DNA (ctDNA) analysis were key discussion points at the 2025 ASCO Annual Meeting. Updated results from the phase 3 EV-302 trial were also presented with impressive outcomes among pati... ...
